- Home
- ICLR vs RPRX Comparison
ICLR vs RPRX Comparison
Compare ICLR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- RPRX
- Stock Information
- Founded
- ICLR 1990
- RPRX 1996
- Country
- ICLR Ireland
- RPRX United States
- Employees
- ICLR N/A
- RPRX N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ICLR Health Care
- RPRX Health Care
- Exchange
- ICLR Nasdaq
- RPRX Nasdaq
- Market Cap
- ICLR 13.7B
- RPRX 15.6B
- IPO Year
- ICLR 1998
- RPRX 2020
- Fundamental
- Price
- ICLR $186.17
- RPRX $36.03
- Analyst Decision
- ICLR Buy
- RPRX Strong Buy
- Analyst Count
- ICLR 15
- RPRX 4
- Target Price
- ICLR $210.64
- RPRX $44.50
- AVG Volume (30 Days)
- ICLR 1.0M
- RPRX 5.2M
- Earning Date
- ICLR 10-22-2025
- RPRX 11-05-2025
- Dividend Yield
- ICLR N/A
- RPRX 2.44%
- EPS Growth
- ICLR 13.11
- RPRX 54.86
- EPS
- ICLR 9.73
- RPRX 2.32
- Revenue
- ICLR $8,089,820,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- ICLR N/A
- RPRX $35.14
- Revenue Next Year
- ICLR $1.42
- RPRX $1.24
- P/E Ratio
- ICLR $19.56
- RPRX $15.51
- Revenue Growth
- ICLR N/A
- RPRX 3.02
- 52 Week Low
- ICLR $125.10
- RPRX $24.05
- 52 Week High
- ICLR $303.69
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- ICLR 59.53
- RPRX 51.05
- Support Level
- ICLR $161.70
- RPRX $35.36
- Resistance Level
- ICLR $197.05
- RPRX $36.67
- Average True Range (ATR)
- ICLR 6.49
- RPRX 0.74
- MACD
- ICLR 2.00
- RPRX 0.08
- Stochastic Oscillator
- ICLR 70.56
- RPRX 68.36
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.